Combined Oral Contraceptives and Vascular Thrombosis: A Single-Center Experience.
combined oral contraceptives
dvt
pe
thrombosis
women
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
accepted:
12
06
2022
entrez:
15
7
2022
pubmed:
16
7
2022
medline:
16
7
2022
Statut:
epublish
Résumé
Background Combined oral contraceptives (COCs) are frequently prescribed for contraception, to regulate ovulation and treat endometriosis, and to control menopausal symptoms. A major risk of hormonal contraceptives is vascular thrombosis. Methods A retrospective chart review of female patients with deep vein thrombosis (DVT), pulmonary embolism (PE), or other sites of thrombosis or emboli seen in the thrombosis clinic of the department of internal medicine at a tertiary care hospital in Saudi Arabia between March 2010 and February 2015 was performed to identify and characterize which women were taking COCs. Results Of 1,008 patients treated for DVT, PE, or other sites of thrombosis or emboli, 100 (9.9%) were taking COCs. Venous (98%) and arterial (2%) thromboses were seen. Overall, 62% of the patients experienced a DVT and 26% pulmonary emboli, and 20% of the patients experienced unusual sites of thrombosis. Furthermore, 53% were obese or morbidly obese. The incidence of venous thrombosis was the highest during the first year of COC use (73%). Of the patients, 8% had thrombophilia. Conclusion This study characterizes Saudi women with thrombotic events taking COCs and identifies risk factors, including unusual sites of thrombosis. Most patients experienced the vascular event during the first year of taking COCs. Age of 40-50 years, obesity, and thrombophilia were the commonly observed risk factors.
Identifiants
pubmed: 35836444
doi: 10.7759/cureus.25865
pmc: PMC9275533
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e25865Informations de copyright
Copyright © 2022, AlSheef et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Best Pract Res Clin Endocrinol Metab. 2013 Feb;27(1):35-45
pubmed: 23384744
Ann Intern Med. 2009 Aug 4;151(3):167-75
pubmed: 19652186
Br J Haematol. 2007 Oct;139(2):289-96
pubmed: 17897305
Arch Intern Med. 1998 Mar 23;158(6):585-93
pubmed: 9521222
Semin Reprod Med. 2008 Jan;26(1):111-20
pubmed: 18181089
Lancet. 1997 Apr 26;349(9060):1202-9
pubmed: 9130941
BMJ. 2011 Oct 25;343:d6423
pubmed: 22027398
Arch Intern Med. 1991 May;151(5):933-8
pubmed: 2025141
J Thromb Haemost. 2007 Apr;5(4):692-9
pubmed: 17367492
Semin Thromb Hemost. 2011 Nov;37(8):885-96
pubmed: 22198853
Saudi Med J. 2020 Oct;41(10):1063-1069
pubmed: 33026046
Front Neurol. 2015 Feb 02;6:7
pubmed: 25699010
Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):700-3
pubmed: 10073976
N Engl J Med. 2012 Jun 14;366(24):2257-66
pubmed: 22693997
BMJ. 2009 Aug 13;339:b2890
pubmed: 19679613
Cochrane Database Syst Rev. 2014 Mar 03;(3):CD010813
pubmed: 24590565
Am J Hematol. 2008 Feb;83(2):97-102
pubmed: 17726684
Lancet. 1994 Nov 26;344(8935):1453-7
pubmed: 7968118
Blood. 2014 Dec 11;124(25):3685-91
pubmed: 25320239
Clin Gastroenterol Hepatol. 2010 Feb;8(2):200-5
pubmed: 19782767
BMJ. 2009 Aug 13;339:b2921
pubmed: 19679614
Circulation. 2003 Jun 17;107(23 Suppl 1):I9-16
pubmed: 12814980
Am J Obstet Gynecol. 1999 Nov;181(5 Pt 1):1263-9
pubmed: 10561657
Thromb Res. 2011 Feb;127 Suppl 3:S30-4
pubmed: 21262435
BMJ. 2012 May 10;344:e2990
pubmed: 22577198
Thromb Haemost. 2003 Mar;89(3):493-8
pubmed: 12624633